Local News

• Cardiac Science initiates voluntary field corrective action of certain AEDs  Cardiac Science that it has initiated a worldwide voluntary field corrective action of certain automated external defibrillators (AEDs) manufactured between August 2006 and March 2007.
  Cardiac Science Corporation October 13, 2008  
• GE Healthcare and Boston Scientific collaborate on cardiovascular imaging  GE Healthcare and intravascular ultrasound market leader Boston Scientific announced a collaboration that enables improved intravascular ultrasound workflow between the GE Healthcare Innova(R) Cardiovascular X-ray System and the Boston Scientific iLab(R) Ultrasound Imaging System.
  Boston Scientific Corporation October 13, 2008  
• Znomics builds patent estate for proprietary zebrafish technologies  Znomics announced that it has reached a significant research development milestone resulting in the company seeking patent protection for its proprietary zebrafish technologies.
  Znomics, Inc. October 13, 2008  
• Znomics announces purchase of $50,000 of its common stock by directors and officers  Znomics announced that it has agreed to sell, and certain officers and directors of the company agreed to purchase, the number of shares equal to the aggregate offering price of $50,000 divided by the last sale price of the company's common stock on October 16, 2008.
  Znomics, Inc. October 13, 2008  
• Abbott announces new $5 billion share repurchase program  Abbott's board of directors has authorized the repurchase of up to $5 billion of the corporation's common stock. The purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.
  Abbott October 13, 2008  
• New data shows Abbott's bioabsorbable drug eluting stent is absorbed within two years  Abbott announced trial data demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries.
  Abbott October 13, 2008  
• OncoGenex achieves key regulatory milestone for lead product candidate, OGX-011  OncoGenex announced that it concluded a meeting with the FDA on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
  OncoGenex Pharmaceuticals Inc. October 13, 2008  
• Cell Therapeutics to request a hearing with NASDAQ  Cell Therapeutics announced that the Company intends to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with NASDAQ Marketplace Rule 4450(b)(1)(A), which requires a minimum market value of listed securities of $50 million.
  Cell Therapeutics, Inc. October 10, 2008  
• Angiotech's corporate partner, Boston Scientific, announces FDA approval  Angiotech Pharmaceuticals reported that its corporate partner, Boston Scientific, has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS(R) Liberté(R) Paclitaxel-Eluting Coronary Stent System.
  Angiotech Pharmaceuticals, Inc. October 10, 2008  
• Wyeth wins Philadelphia diet drug trial involving claim of PPH  Wyeth announced that the jury in the case of Danny Crowder (Individually and as Administrator of the Estate of Edna Faye Crowder) v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth.
  Wyeth October 10, 2008  

   (next 10 articles)